Designing CD4 immunoadhesins for AIDS therapy

Nature. 1989 Feb 9;337(6207):525-31. doi: 10.1038/337525a0.

Abstract

A newly-constructed antibody-like molecule containing the gp120-binding domain of the receptor for human immunodeficiency virus blocks HIV-1 infection of T cells and monocytes. Its long plasma half-life, other antibody-like properties, and potential to block all HIV isolates, make it a good candidate for therapeutic use.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Acquired Immunodeficiency Syndrome / immunology
  • Acquired Immunodeficiency Syndrome / metabolism
  • Acquired Immunodeficiency Syndrome / therapy*
  • Adjuvants, Immunologic / chemical synthesis*
  • Adjuvants, Immunologic / metabolism
  • Adjuvants, Immunologic / pharmacokinetics
  • Animals
  • Antigens, Surface / administration & dosage
  • Antigens, Surface / chemical synthesis
  • Antigens, Surface / immunology*
  • Binding Sites, Antibody
  • Binding, Competitive
  • Cell Adhesion Molecules
  • Cell Line
  • Drug Design
  • HIV Envelope Protein gp120
  • Half-Life
  • Humans
  • Immunoglobulin G* / administration & dosage
  • Immunoglobulin G* / metabolism
  • Mice
  • Rabbits
  • Receptors, Complement / analysis
  • Receptors, Fc / analysis
  • Receptors, HIV
  • Receptors, Virus / administration & dosage
  • Receptors, Virus / immunology*
  • Retroviridae Proteins / metabolism

Substances

  • Adjuvants, Immunologic
  • Antigens, Surface
  • Cell Adhesion Molecules
  • HIV Envelope Protein gp120
  • Immunoglobulin G
  • Receptors, Complement
  • Receptors, Fc
  • Receptors, HIV
  • Receptors, Virus
  • Retroviridae Proteins